OKC
Odontogenic Tumor
Intraosseous Salivary Gland Neoplasm
Metastatic tumor
Myoepithelioma
IHC - S100 protein, cytokeratin, GFAP and alpha smooth muscle actin (SMA) positive
DX Intraosseous SGT = 4 Main Criteria
* No pre-existing or concurrent primary SGT
* Origin of tumor from submucosal glands of palate or maxillary antrum or derivation from a primary antral tumor must be excluded
* Cortical bone integrity around tumor proved by imaging technique
* Histologic confirmation of salivary gland tumor
Myoepithelioma Demographics
* 30-90 yo (median 53)
* M=F
* Rare ~1.5% of all tumors of major & minor SG's
* Intraosseous extremely rare - search of Lit 7 cases reported
* Variant of Pleomorphic Adenoma
* Difference is lack of ductal elements <5-10% ducts
* Occasionally undergoes malignant transformation
* Regezi, Joseph A., Oral Pathology: Clinical Pathologic Correlations, 5th Edition. Saunders Book Company, 10-2007
* Intraosseous myoepithelioma of the maxilla: clinicopathologic features and therapeutic considerations. Cuesta Gil M, et al. J Oral Maxillofac Surg. 2008 Apr;66(4):800-3
* Intraosseous myoepithelial neoplasms of the maxilla: diagnostic and therapeutic considerations in 5 South African patients. Ferretti C, et al. J Oral Maxillofac Surg. 2003 Mar;61(3):379-86